The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Gilead Sciences on Monday lowered its full-year sales outlook, citing slower-than-expected demand for its key hepatitis C drugs, and said second-quarter profits fell 22 percent.
The biotechnology company's shares, which had closed 2.3 percent higher, fell 4 percent to $85 after hours.
Product sales fell to $7.65 billion from $8.13 billion in the year-ago quarter, Gilead said in a statement. Sales of hepatitis C drugs Sovaldi and Harvoni dropped to $4 billion from $4.9 billion. Wall Street analysts, on average, had forecast hepatitis C sales of $4.09 billion, according to a poll by ISI Evercore.
Gilead lowered its 2016 product sales outlook to between $29.5 billion and $30.5 billion, from a previous range of $30 billion to $31 billion. The company said non-government U.S. health insurance plans were still limiting the number of patients who get the treatments, which many critics have said are far too expensive.
Other factors behind the lower sales forecast include weaker hepatitis C drug pricing in some European markets, a trend toward shorter treatments and the loss of market share to competition, Chief Financial Officer Robin Washington told analysts on conference call after the results were released.
Gilead drew fire more than two years ago when it charged $84,000 per course of treatment for Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease.
The number of U.S. patients who started undergoing treatment with hepatitis C drugs was little changed from the first quarter, suggesting that the market has stabilized, ISI Group analyst Mark Schoenebaum said in a research note on Monday.
Gilead's quarterly net profit fell to $3.5 billion from $4.5 billion a year earlier. Adjusting for one-time items, Gilead earned $3.08 per share, which beat analysts' average estimate of $3.02, according to Thomson Reuters I/B/E/S.
An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should be treated with the new drugs.
The virus is spread by contact with contaminated blood of an infected person, by sharing needles or other equipment to inject drugs. Most patients have no symptoms, but some have fatigue, nausea, loss of appetite, and yellowing of the eyes and skin.